Cipher Pharmaceuticals Inc.
CPHRF
$12.09
-$0.47-3.74%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.22% | 89.17% | 114.78% | 78.45% | 57.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.22% | 89.17% | 114.78% | 78.45% | 57.66% |
| Cost of Revenue | 8.30% | 152.73% | 197.61% | 167.28% | 127.57% |
| Gross Profit | 67.71% | 74.04% | 95.45% | 57.99% | 41.01% |
| SG&A Expenses | 33.22% | 101.17% | 218.27% | 172.89% | 125.59% |
| Depreciation & Amortization | 80.03% | 149.62% | 529.12% | 373.15% | 227.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.63% | 124.89% | 240.94% | 188.70% | 134.94% |
| Operating Income | 114.90% | 29.24% | -12.39% | -33.77% | -23.82% |
| Income Before Tax | 480.81% | 2.17% | -53.08% | -85.52% | -76.70% |
| Income Tax Expenses | -18.35% | -20.42% | 38.17% | 24.30% | -11.53% |
| Earnings from Continuing Operations | 136.72% | 9.50% | -46.27% | -59.23% | -43.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 136.72% | 9.50% | -46.27% | -59.23% | -43.36% |
| EBIT | 114.90% | 29.24% | -12.39% | -33.77% | -23.82% |
| EBITDA | 103.68% | 55.36% | 37.20% | 4.86% | 2.19% |
| EPS Basic | 126.75% | 3.19% | -48.91% | -60.00% | -42.55% |
| Normalized Basic EPS | 185.51% | -11.93% | -37.05% | -63.88% | -54.21% |
| EPS Diluted | 125.22% | 4.18% | -48.52% | -59.71% | -42.03% |
| Normalized Diluted EPS | 185.92% | -12.71% | -37.70% | -64.25% | -54.51% |
| Average Basic Shares Outstanding | 3.49% | 5.17% | 4.82% | 1.74% | -1.01% |
| Average Diluted Shares Outstanding | 4.36% | 4.97% | 4.71% | 1.58% | -1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |